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BACKGROUND: Ischemia reperfusion injury (I/RI) is a common 
complication of cardiovascular diseases. Resolution of detrimental I/
RI-generated prothrombotic and proinflammatory responses is essential 
to restore homeostasis. Platelets play a crucial part in the integration of 
thrombosis and inflammation. Their role as participants in the resolution 
of thromboinflammation is underappreciated; therefore we used 
pharmacological and genetic approaches, coupled with murine and clinical 
samples, to uncover key concepts underlying this role.
METHODS: Middle cerebral artery occlusion with reperfusion was performed 
in wild-type or annexin A1 (AnxA1) knockout (AnxA1−/−) mice. Fluorescence 
intravital microscopy was used to visualize cellular trafficking and to monitor 
light/dye–induced thrombosis. The mice were treated with vehicle, AnxA1 
(3.3 mg/kg), WRW4 (1.8 mg/kg), or all 3, and the effect of AnxA1 was 
determined in vivo and in vitro.
RESULTS: Intravital microscopy revealed heightened platelet adherence and 
aggregate formation post I/RI, which were further exacerbated in AnxA1−/− 
mice. AnxA1 administration regulated platelet function directly (eg, via 
reducing thromboxane B2 and modulating phosphatidylserine expression) 
to promote cerebral protection post-I/RI and act as an effective preventative 
strategy for stroke by reducing platelet activation, aggregate formation, and 
cerebral thrombosis, a prerequisite for ischemic stroke. To translate these 
findings into a clinical setting, we show that AnxA1 plasma levels are reduced 
in human and murine stroke and that AnxA1 is able to act on human 
platelets, suppressing classic thrombin-induced inside-out signaling events 
(eg, Akt activation, intracellular calcium release, and Ras-associated protein 
1 [Rap1] expression) to decrease αIIbβ3 activation without altering its surface 
expression. AnxA1 also selectively modifies cell surface determinants (eg, 
phosphatidylserine) to promote platelet phagocytosis by neutrophils, thereby 
driving active resolution. (n=5–13 mice/group or 7–10 humans/group.)
CONCLUSIONS: AnxA1 affords protection by altering the platelet phenotype 
in cerebral I/RI from propathogenic to regulatory and reducing the propensity 
for platelets to aggregate and cause thrombosis by affecting integrin (αIIbβ3) 
activation, a previously unknown phenomenon. Thus, our data reveal a novel 
multifaceted role for AnxA1 to act both as a therapeutic and a prophylactic drug 
via its ability to promote endogenous proresolving, antithromboinflammatory 
circuits in cerebral I/RI. Collectively, these results further advance our knowledge 
and understanding in the field of platelet and resolution biology.
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Inflammation and thrombosis play crucial roles in the pathophysiological cascade of cardiovascular diseases, especially in ischemic stroke.1 The interde-
pendent connection of both processes in eliciting a 
detrimental prothrombotic and proinflammatory state 
after ischemia reperfusion injury (I/RI) has led to the 
concept of thromboinflammation.1–4 The rapid inflam-
matory response that develops during reperfusion leads 
to subsequent cerebral microvascular dysfunction with 
platelets adhering at ischemic vascular lesions, thereby 
increasing the risk of secondary thrombotic events and 
further tissue injury.5
Administration of agents that ameliorate the aggres-
sive thromboinflammatory state rapidly after ischemic 
insults represent attractive novel treatment strategies for 
I/RI.1–3 Although peripheral inflammatory cells such as 
neutrophils and monocytes have been implicated in the 
resolution of thromboinflammation, the role that plate-
lets may play in this process is largely undefined thus far.
The active process of resolution involves a tightly or-
chestrated series of highly regulated biochemical me-
diators,6–8 such as endogenous annexin A1 (AnxA1) and 
lipoxin A4.
9 In humans, the biological effects of AnxA1 
and its mimetic peptides are mediated through 3 G-
protein–coupled receptors, termed formyl peptide re-
ceptors (FPR1, FPR2, FPR3).10 Although the protective 
effects of AnxA1 have been well characterized in differ-
ent disease models,6–12 only a few studies (with mixed 
outcomes) have focused on the effect(s) of AnxA1 (pre-
viously termed Lipocortin 1) on platelet function, with a 
particular emphasis on the of AnxA1 in the regulation 
of intracellular phospholipase A2.
13–20 Thus, we wanted 
to further investigate the effect(s) of AnxA1 on plate-
let function (eg, platelet adhesion, activation, aggrega-
tion, and thrombosis) in the context of the resolution of 
thromboinflammation.
Previously, our findings elucidated that targeting li-
poxin A4 receptor Fpr2/ALX (murine orthologue to hu-
man FPR2/ALX) inhibits cerebral inflammation in a fo-
cal transient I/RI model.9 However, we and others have 
yet to discern the effect(s) of AnxA1 on platelets and 
whether strategies focused on the AnxA1-Fpr2/ALX 
axis may substantially add to the development of new 
treatment possibilities for I/RI. We were therefore inter-
ested in closing this knowledge gap.
Herein, we found a novel modulatory role of AnxA1 
on platelets. Specifically, AnxA1 administration reduced 
both platelet adherence to the inflamed cerebral endo-
thelium after stroke and regulated the state of platelet 
activation. AnxA1 moderated platelet aggregation (by re-
ducing platelet–platelet aggregate formation), diminished 
the prothrombotic potential of platelets (reflected in de-
creased thromboxane B2 production and reduced phos-
phatidylserine [PS] expression), and suppressed active in-
tegrin αIIbβ3 levels, thereby reducing the risk of thrombotic 
events. We also present novel data regarding the ability of 
AnxA1 to promote the phagocytosis of platelets by neu-
trophils. Finally, we report a previously unknown role for 
AnxA1 as a preventative strategy both for cerebral I/RI (by 
its ability to reduce cerebral thrombosis, a prerequisite for 
stroke) and for subsequent thrombotic events after I/RI.
METHODS
A detailed Methods section is provided in the online-only 
Data Supplement. The data that support the findings of this 
study are available from the corresponding author on reason-
able request.
Animals
Animal experiments complied with ARRIVE (Animal Research: 
Reporting In Vivo Experiments) guidelines and followed the 
European Union Directive (2010/63/EU) or LSUHSC-S IACUC. 
Wild-type (WT) C57BL/6 mice or AnxA1−/− mice21 were used.
Human Samples
The study was approved by the institutional review board of 
the LSUHSC-S (STUDY00000572 and STUDY00000261) and 
conducted in accordance with the Declaration of Helsinki. 
Written informed consent was obtained from the participants.
Clinical Perspective
What Is New?
• The findings of lower plasma levels of the anti-
inflammatory/proresolving protein annexin A1 
(AnxA1) among patients with acute ischemic 
stroke may help to explain the exacerbated throm-
boinflammatory response observed in ischemia 
reperfusion injury.
• Administration of AnxA1 promotes cerebral pro-
tection against thromboinflammation and devel-
opment of subsequent thrombotic events after 
stroke.
• AnxA1 is able to reduce platelet activation and 
thrombosis via the suppression of integrins (the 
main platelet receptors involved in platelet adhe-
sion and aggregation).
What Are the Clinical Implications?
• Our findings regarding the multifaceted role that 
AnxA1 plays in stroke may provide a means to 
extend the intervention window for both medical 
and surgical therapeutic modalities and make the 
intervention safer for patients.
• Furthermore, the protective effect of AnxA1 may 
improve the outcome of stroke intervention by lim-
iting the development of thrombotic events during 
and after the intervention.
• Our data could pave the way for novel and more 
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Receptor Agonists and Drug Treatment
Vehicle (saline), whole protein AnxA1 (3.3 mg/kg,21 Cambridge 
Research Biochemicals, Cleveland, UK), and WRW4 (1.8 mg/
kg,22 Tocris, Bristol, UK) were administered intravenously at 
the start of cerebral reperfusion.
AnxA1 Quantification in Plasma
Human or murine AnxA1 ELISA kits (MyBioSource) were used 
to quantify the plasma levels of AnxA1 (see online-only Data 
Supplement).
Transient Focal Middle Cerebral Artery 
Occlusion With Reperfusion
Transient focal middle cerebral artery occlusion with reper-
fusion (tMCAo/R) was performed for 60 min followed by 4 
or 24 h of reperfusion according to standard operating pro-
cedure in our laboratory.9 Sham animals were subject to the 
same operative procedure without occlusion.
Platelet and Leukocyte Labeling
Platelets were isolated from donor mice, ex vivo fluorescently 
labeled with carboxyfluorescein succinimidyl ester (90 µmol/L, 
10 min, Sigma–Aldrich, St Louis, MO), and injected into recip-
ient mice, followed by 0.02% rhodamine 6G (Sigma–Aldrich) 
to label circulating leukocytes in vivo.9
Neutrophil Depletion
Neutropenia was induced using mouse antineutrophil serum 
(1A8; BioXCell, West Lebanon, NH; 150 μg/mouse).23
Neutrophil Isolation and Adoptive Transfer
Neutrophils were isolated, labeled with CellTracker24 
(ThermoFisher, Waltham, MA), and treated with WRW4 (10 
μmol/L, 10 min, Tocris) before injection into recipient neutro-
penic tMCAo/R mice. The mice were then treated with AnxA1 
(see online-only Data Supplement).20
Cerebral Intravital Fluorescence 
Microscopy
Intravital microscopy was performed according to standard 
operating procedure in our laboratory using a Zeiss Axioskop 
microscope (Zeiss, New York, NY; see online-only Data 
Supplement).9
Confocal Microscopy
To visualize endothelial platelet–neutrophil aggregate (PNA) 
formation in vivo, the mice were injected with specific anti-
bodies to label: neutrophils (eFluor 488 [green]–labeled anti-
mouse Ly-6G, 2 μg/mouse; eBioscience, San Diego, CA) and 
platelets (Dylight 649 [red]-labeled antimouse CD42, 1 μg/
mouse; Emfret Analytics, Eibelstadt, Germany; see online-only 
Data Supplement).9
Systemic PNA Assessment
Systemic PNAs were assessed by flow cytometry in blood 
from tMCAo/R mice treated with either vehicle or AnxA1. 
Leukocytes were labeled with rat antimouse CD45.2–
FITC, Gr-1–PE, and F4/80–eFluor450 and isotype controls 
(eBioscience), and platelets were labeled with CD41-APC (see 
online-only Data Supplement).21
Assessment of Activated Platelets by 
Flow Cytometry
Two-color staining of activated murine and human αIIbβ3, 
cell surface CD41a, P-selectin, and AnxAV (to measure PS) 
was performed using flow cytometry (see online-only Data 
Supplement).26
Platelet Aggregation Assay
Platelet-rich plasma was freshly collected from tMCAo/R mice 
treated with either vehicle or AnxA1 and used to monitor 
platelet aggregation velocity after agonist exposure using a 
laser-particle analyzer (Lumex Ltd., St. Petersburg, Russia; see 
online-only Data Supplement).27
Thrombosis
Thrombosis in cerebral vessels was induced using the light/
dye thrombosis model (see online-only Data Supplement).25 
Thirty minutes before onset of thrombosis, the mice were 
treated with vehicle or AnxA1 (1 µg/mouse).
Ras-Associated Protein 1 Activity
Ras-associated protein 1 (Rap1) activity assay was performed 
according to instructions from the supplier (see online-only 
Data Supplement).
Western Blotting
Freshly prepared platelets (1×107 cells) were incubated with 
AnxA1 (100 ng/1×106) platelets for 15 min followed by 
thrombin stimulation (0.1 U) for 3 min. Platelet pellets were 
prepared for western blotting for Akt and FPR2 (see online-
only Data Supplement).
Measurement of Intracellular Ca2+ Levels 
in Fluo-3-Acetoxymethyl Ester
Washed platelets (1×106) were stained with fluo-3-acetoxy-
methyl ester (5 μmol/L) for 30 min at 37°C as previously 
described,28 and some samples were incubated with vehicle 
or AnxA1 (100 ng) before thrombin stimulation. Fluorescent 
intensity of fluo-3-acetoxymethyl ester–loaded platelets was 
immediately recorded using BD LSR II as previously described 
(see online-only Data Supplement).28
Phagocytosis Assay
Neutrophil phagocytosis of platelets was performed using the 
IncuCyte ZOOM (Essen BioScience, Inc., Ann Arbor, MI; see 
online-only Data Supplement).
Cytokines in Plasma and Brain Tissue
After 24 h of reperfusion, plasma and brain hemisphere 
homogenates were obtained. The levels of pro- and 
anti-inflammatory cytokines and thromboxane B2 were 
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After 24 h of reperfusion, the brains were removed and 
stained with 2% 2,3,5-triphenyltetrazolium chloride (Sigma–
Aldrich). Sections were photographed, and digitized images 
of each brain section (and the infarcted area) were quantified 
using National Institutes of Health 1.57 Image software.9
Neurological Score
A 5-point neurological deficit score was used: 0 indicates no 
deficit; 1, failure to extend right paw; 2, circling to the right; 
3, falling to the right; and 4, unable to walk spontaneously.9 
The mice were evaluated at 24 h of reperfusion.
Blood–Brain Barrier Permeability
Blood–brain barrier (BBB) permeability was assessed using 
Evans blue extravasation.9 BBB permeability was normalized 
by dividing tissue Evans blue concentration (micrograms per 




Plasma was collected from WT and AnxA1−/− mice, and 
thrombin–antithrombin was measured using thrombin–anti-
thrombin complex ELISAs (Assay Pro, Saint Charles, MO).
D-Dimer
Plasma was collected from WT and AnxA1−/− mice, and 
D-dimer was measured using an Asserachrom D-dimer kit 
(no. 00947; Diagnostica Stago, Parsippany, NJ).
Statistical Analysis
All data were tested to follow a normal distribution using a 
Kolmogorov–Smirnov test of normality with a Dallal–Wilkinson–
Lillie for the corrected p value. The data that passed the nor-
mality assumption was analyzed using Student t test (2 groups) 
or ANOVA with Bonferroni post-tests (more than 2 groups). 
The data that failed the normality assumption were analyzed 
using the nonparametric Mann–Whitney U test (2 groups) or 
Kruskal–Wallis with Dunn’s test (more than 2 groups). Analysis 
was performed using Graph Pad Prism5 software (San Diego, 
CA). The data are shown as mean values ± SEM or median with 
interquartile range (neurological score only). The differences 
were considered statistically significant at a value of P<0.05.
RESULTS
Mice Lacking AnxA1 Possess Augmented 
Platelet Responses Coupled With 
Increased Cerebral Damage After I/RI
To determine whether a deletion of AnxA1 impacts 
platelet recruitment and the I/RI-elicited inflamma-
tory response and to extend the macroscopic sever-
ity of cerebral I/RI, we first performed 60-min tMCAo 
followed by 4 or 24 h reperfusion in AnxA1−/− mice. 
AnxA1−/− mice displayed a significant increase in plate-
let adhesion to the cerebral endothelium at both time 
points after reperfusion (Figure 1A). This was coupled 
to heightened platelet-–leukocyte aggregate formation 
(Figure  1B) and leukocyte adhesion (Figure IA in the 
online-only Data Supplement). These observations were 
not related to changes in hemodynamic parameters be-
cause no differences among mouse genotypes were de-
tected (Table I in the online-only Data Supplement). Fur-
thermore, the effects on platelets were also paralleled 
with increased stroke severity as displayed by increased 
neurological score, infarct volume, and BBB permeabil-
ity in both the contralateral and ipsilateral hemispheres 
of tMCAo/R AnxA1−/− mice (Figure IC through IE in the 
online-only Data Supplement), suggesting that deletion 
of the AnxA1 gene is associated with increased neu-
rovascular inflammation after cerebral I/RI. The AnxA1 
gene deletion is also not associated with spontaneous 
thrombosis and bleeding because plasma levels of both 
thrombin–antithrombin III complex (an indicator of 
thrombin production and accurately reflects the activa-
tion of coagulation)29,30 and D-dimer (an indicator of 
ongoing fibrinolysis)30,31 were similar to their WT coun-
terparts (Figure II in the online-only Data Supplement).
In line with the exacerbated cerebral inflammatory 
state, plasma cytokine levels of interleukin (IL)-1β, TNFα, 
Figure 1. Platelet and platelet–leukocyte interactions in the cerebral 
microcirculation are heightened in annexin A1 knockout (AnxA1−/−) 
mice after ischemia reperfusion injury (I/R). 
Wild-type (WT) and AnxA1−/− mice were subjected to transient middle cerebral 
artery occlusion for 60 min, followed by 4- or 24-h reperfusion. Intravital 
fluorescence microscopy was performed to assess cellular interactions in 
the cerebral microcirculation (pial vessels) of mice subjected to cerebral I/R. 
Platelets were labeled with carboxyfluorescein succinimidyl ester (90 µmol/L), 
and leukocytes were labeled with rhodamine 6G (0.02%). Platelet interac-
tions were quantified in terms of numbers (no.) of adherent platelets on the 
endothelium (A, cells stationary for ≥2 s) and platelets interacting directly 
with adherent leukocytes on the endothelium (B), termed platelet–leukocyte 
aggregates (PLAs). The data are means±SEM of 6 mice per group with 2 to 
3 vessels per mouse and assessed by ANOVA with Bonferroni post hoc test 
(A) or Mann–Whitney test (B). *P<0.05, ***P<0.001, and ****P<0.0001 vs 
sham control of the same genotype. #P<0.05, ##P<0.01, and ####P<0.0001 




 http://ahajournals.org by on July 23, 2021
Senchenkova et al Annexin A1 Modulates Platelet Function in Stroke
Circulation. 2019;140:319–335. DOI: 10.1161/CIRCULATIONAHA.118.039345 July 23, 2019 323
ORIGINAL RESEARCH 
ARTICLE
and IL-6 were all increased in AnxA1−/− mice compared 
with WT mice under the same conditions. There were 
no differences found in CCL2 or IL-10 levels (Table 1). 
Local cytokine levels were all significantly elevated in 
the left (injured) hemisphere of WT and AnxA1−/− mice 
after I/RI (Table 1). Interestingly, AnxA1−/− mice also dis-
played higher IL-10 levels in the left hemisphere versus 
the right, suggesting a possible compensatory mech-
anism. However, both TNFα and IL-1β levels were el-
evated in AnxA1−/− mice compared with WT mice. No 
cytokine was above control values in the contralateral 
hemisphere of either WT or AnxA1−/− mice, suggest-
ing that these inflammatory mechanisms are confined 
within the ischemic region (ie, ipsilateral side).
Plasma levels of AnxA1 were found to be lower in 
stroke patients (Table 2) versus the control group (Fig-
ure  2A). This reduced AnxA1 level was also mirrored 
in plasma samples obtained from WT mice subjected 
to tMCAo for 60 min followed by 24 h of reperfusion 
(Figure 2B), supporting the translation of our findings 
to a clinical setting.
Blocking Fpr2/ALX Inhibits the Effect 
of AnxA1 on Ischemia-Induced Platelet 
Interactions
We sought to determine whether AnxA1 administra-
tion could alter platelet–endothelial and platelet–leu-
kocyte interactions. Figure 3 shows that administration 
of AnxA1 to WT mice subjected to tMCAo decreases 
both intravascular platelet adhesion (Figure  3A) and 
PNA accumulation (Figure 3B and 3C) on the cerebral 
endothelium when compared with saline-injected ani-
mals. In addition, these protective effects produced by 
AnxA1 were translated in reduced neurological score 
(assessed 24 h after reperfusion), which correlated with 
decreased infarct volumes (data not shown).
The importance of Fpr2/ALX as the key receptor 
in mediating effects of AnxA1 has been widely stud-
ied.8–12,19–22 However, this has not been shown in the 
Table 1. Cytokine Profiles Are Augmented in AnxA1−/− Mice Ischemia Reperfusion Injury
 IL-1β TNFα CCL2 IL-10 IL-6
WT I/R Plasma 369±24.7 171±36.8 292±33.0 53±10.8 296±29.7
AnxA1−/− I/R Plasma 644±48.9* 297±26.9† 332±21.1 54.7±9.4 506.5±76.1†
WT I/R Brain (right) 87±5.8 34±7.5 221.4±16.6 196±22.0 67±12.2
Brain (left) 173±28.5‡ 75±8.1‡ 5365±158.1§ 251±25.4 2015±72.3‖
AnxA1−/− I/R Brain (right) 112.6±7.3 29±2.5 507±45.1 157±19.1 63±8.3
Brain (left) 317.5±20.06‖¶ 156±20.6‖# 5488±338.6§ 200±13.2‡ 3138±186.7‖¶
The data are means±SEM of 6 mice per group of mice undergoing cerebral 60 min of ischemia + 24 h of reperfusion and assessed by Student t test (all plasma 
samples), ANOVA with Bonferroni post hoc test (brain: interleukin [IL]-1 beta [IL-1β], tumor necrosis factor-alpha [TNFα], IL-10, IL-6), or Kruskal–Wallis with Dunn test 
(brain: CCL2). The values are expressed as picograms per milliliter for plasma and picograms per milligrams for tissue. AnxA1−/− indicates annexin A1 knockout mice; IL, 
interleukin; I/R, ischemia/reperfusion; left, left (injured) hemisphere (ipsilateral); right, right hemisphere (contralateral); TNF, tumor necrosis factor; and WT, wild-type mice.
*P<0.001 vs WT plasma.
†P<0.05 vs WT plasma.
‡P<0.05 vs same genotype right side.
§P<0.01 vs same genotype right side.
‖P<0.0001 vs same genotype right side.
¶P<0.0001 vs WT left side.
#P<0.001 vs WT left side.
Table 2. Demographic and Clinical Characteristics of Stroke Patients
Stroke Patients
Number 11
Sex 5 male, 6 female
Age range, y 45–89
Comorbidities/risk factors
  Diabetes mellitus 4 of 11 (36.36%)
  Hypertension 10 of 11 (90.90%)
  Previous CVAs 2 of 11 (18.18%)
  Smoking 7 of 11 (63.63%)
Prognosis
  Admission NIHSS score (SEM) 14.70±1.25
Hematologic parameters
  Leukocytosis 4 of 11 (36.36%)
  Thrombocytosis 0 of 11 (0%)
Stroke cause
  Cardiac 4 of 11 (36.36%)
  Carotid 3 of 11 (27.27%)
  Intracranial 4 of 11 (36.36%)
Stroke location of occlusion site
  MCA 6 of 11 (54.54%)
  ICA 4 of 11 (36.36%)
  PCA of BA 1 of 11 (9.09%)
Prestroke antiplatelet drugs
  Aspirin 6 of 11 (54.54%)
  Clopidogrel 2 of 11 (18.18%)
BA indicates basilar artery; CVA, cerebrovascular accident; ICA, internal 
carotid artery; MCA, middle cerebral artery; NIHSS, National Institute of Health 
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context of platelet function. We found that when coad-
ministered with AnxA1, the selective Fpr2/ALX antago-
nist WRW411 was able to successfully abrogate the pro-
tective actions of AnxA1 on platelet and PNA adhesion 
to the cerebral endothelium (Figure 3A and 3C). These 
data further support the growing body of evidence that 
the protective effects of AnxA1 are mediated through 
Fpr2/ALX and identify a previously unknown effect of 
the AnxA1 Fpr2/ALX pathway to mitigate the throm-
boinflammatory effects of platelets.
AnxA1 Reduces PNA Recruitment via 
Fpr2/ALX
Next we tested whether AnxA1 would inhibit endo-
thelial PNA recruitment via a direct action on neu-
trophil Fpr2/ALX, as reported for another agonist of 
this receptor, aspirin-triggered lipoxin A4.
7 To test this 
hypothesis, isolated neutrophils were infused into 
neutropenic mice after tMCAo, and these mice were 
subsequently treated with AnxA1 or saline vehicle (Fig-
ure  3D). This treatment resulted in reduced cerebral 
endothelial PNA formation (Figure 3E). To further con-
firm that the observed effects were specifically due to 
the actions of AnxA1 on Fpr2/ALX, we repeated the 
experiments in presence of the Fpr2/ALX specific an-
tagonist WRW4. To this end, isolated neutrophils were 
pretreated with WRW4 and then infused into neutro-
penic mice after tMCAo. Animals were subsequently 
treated with AnxA1 or saline vehicle (Figure 3F). These 
experiments showed that selective antagonism of neu-
trophil Fpr2/ALX prevented the ability of AnxA1 to re-
duce PNA recruitment to the cerebral endothelium af-
ter stroke (Figure 3G). We then further tested whether 
these results were specific to local PNA recruitment to 
the damaged cerebral endothelium or whether AnxA1 
might have an additional effect on systemic aggregate 
formation after cerebral I/RI. Interestingly, we found 
that AnxA1 did not affect the percentage of circulat-
ing PNAs within the circulating platelet–leukocyte ag-
gregate population in the blood of mice subjected to 
tMCAo for 60 min followed by 24 h of reperfusion 
(Figure  3H through 3K and Figures III and IV in the 
online-only Data Supplement). These intriguing results 
indicate that although AnxA1 reduces endothelial PNA 
formation in the brain, it is not due to a decrease in the 
number of circulating PNAs.
AnxA1 Inhibits the Prothrombotic 
Activity of Platelets Post-I/RI
Having provided clear evidence that deletion of AnxA1 
is associated with increased platelet and PNA adherence 
after stroke (Figure  1) and administration of AnxA1 
ameliorates the detrimental effects of I/RI by diminish-
ing platelet interactions at the cerebral endothelium, we 
wanted to evaluate the contribution of AnxA1 on plate-
let activation/aggregation after cerebral I/RI. We first 
measured platelet activation by quantifying plasma lev-
els of the thromboxane A2 stable metabolite thrombox-
ane B2. Figure 4A shows that mice treated with AnxA1 
have decreased thromboxane B2 levels in comparison 
with those levels observed in vehicle (saline)–treated 
tMCAo/R mice. Platelets facilitate blood coagulation by 
externalizing PS on their cell surface, and PS exposure is 
directly related to the procoagulant activity of activated 
platelets.33 Figure 4B shows that AnxA1 decreased PS 
exposure (expressed as AnxAV+) on single platelets after 
tMCAo/R (determined by flow cytometry), as well as on 
platelet–platelet aggregates (Figure  4C). Interestingly, 
this effect of AnxA1 on platelet PS exposure was also 
present when platelets were further ex vivo stimulated 
with either thrombin or ADP (Figure 4D and Figure VA 
in the online-only Data Supplement).
AnxA1 Reduces the Velocity at Which 
Platelets Aggregate After Cerebral I/RI
Having shown that AnxA1 reduces the prothrombotic 
activity of platelets from tMCAo/R mice, we next ad-
dressed whether this was related to the ability of plate-
lets to form aggregates. Figure 4E and 4F shows that 
AnxA1-treated tMCAo/R mice exhibited decreased ve-
locity of platelet aggregation to thrombin (and ADP; 
Figure VB and VC in the online-only Data Supplement). 
These data provide further evidence that not only is 
AnxA1 able to reduce the prothrombotic potential 
of platelets, but it is also able to reduce the velocity 
at which platelets form platelet–platelet aggregates, 
Figure 2. Plasma levels of AnxA1 are reduced in human and murine 
stroke. 
Plasma was collected from control volunteers and stroke patients (A) and mice 
with and without stroke (B, transient middle cerebral artery occlusion for 60 
min followed by 24 h of reperfusion). Annexin A1 (AnxA1) levels were assessed 
by ELISA. The data are means±SEM of 7 to 13, with 10 humans per group (8 
samples were collected from control volunteers, but 1 outlier [defined as at least 
2 standard deviations] was removed; 11 samples were collected from stroke pa-
tients, but 1 outlier was removed) and 5 to 13 mice per group and assessed by a 
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Figure 3. Administration of exogenous annexin A1 (AnxA1) moderates platelet interactions in the brain microcirculation after ischemia reperfusion 
injury (I/R). 
Wild-type mice were subjected to transient middle cerebral artery occlusion for 60 min, followed by 24 h of reperfusion (tMCAo/R). A, Vehicle, AnxA1 (3.3 mg/
kg), or WRW4 (1.8 mg/kg) were administered intravenously at the start of reperfusion and numbers (no.) of platelet adhesion (cells stationary for at least 2 s) 
were quantified. B, Representative image of cerebral platelet-neutrophil aggregates (PNAs) 24 h after reperfusion as measured by confocal intravital microscopy. 
Neutrophils (Neuts, arrow) were labeled with eFluor 488 (green)-labeled anti-mouse Ly-6G, 2 μg/mouse. Platelets (arrowhead) were labeled with Dylight 649 (red)-
labeled antimouse CD42, 1 μg/mouse. The scale bar indicates 20 μm. C, Quantification of endothelial-PNAs in the cerebral microcirculation. D, Adoptive transfer 
experiments were performed by injecting neutrophils isolated from donor mice into neutropenic recipient mice. In steps 1 and 2, recipient mice were rendered 
neutropenic by administration of antineutrophil serum (ANS). In step 3, neutropenic mice were subjected to cerebral I/R by tMCAo/R. In step 4, neutrophils were 
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thereby reducing the risk of thrombosis, eg, subsequent 
thrombotic events in stroke.
AnxA1 Thwarts Thrombosis and 
Secondary Thrombotic Events Poststroke
Having assessed the novel anti-inflammatory and anti-
thrombotic effects of AnxA1 on platelets isolated from 
AnxA1-treated mice after cerebral I/RI, we wanted to 
address in vivo whether AnxA1 administration might 
also be effective in reducing the prothrombotic events 
that may ultimately lead to stroke and reducing the 
effect of subsequent thrombotic events after stroke. 
Figure  5A through 5E shows that AnxA1 is able to 
prolong blood flow cessation time in both cerebral ar-
terioles and venules, suggesting that AnxA1 is able to 
modify the thromboinflammatory environment, which 
may lead to ischemic stroke. Given the impact of subse-
quent thrombotic events in stroke, we finally assessed 
whether AnxA1 had a similar impact on thrombus for-
mation in mice after cerebral I/RI. Thus, we set up an 
animal model combining tMCAo with 24 h of reper-
fusion, followed by the light/dye method to measure 
cerebral blood flow cessation time in both cerebral ar-
terioles and venules, to mimic subsequent thrombotic 
events, and to definitively describe the potential for 
AnxA1 to be a treatment strategy in stroke. Figures 5G 
and 5H show that when AnxA1 is given after cerebral I/
RI, it is able to significantly protect against subsequent 
thrombotic events by causing a significant increase in 
blood flow in venules by 45.51% and in arterioles by 
58.09%, respectively.
A Direct Effect of AnxA1 on Human 
Platelets: An Undiscovered Platelet 
Modulator
Finally, to further explore the translational relevance of 
the in vivo findings, we ascertained the direct effect of 
AnxA1 on human isolated platelets. Figure 6A and 6B 
shows that thrombin enhanced the surface levels of 
P-selectin and active αIIbβ3 (as assessed by binding of 
FITC–PAC-1, a monoclonal antibody specific for neo-
epitopes exposed on the activated form of αIIbβ3)
34 on 
platelets, whereas direct treatment with AnxA1 inhib-
ited only active integrin αIIbβ3 levels (P<0.05), with no 
statistically significant effect on P-selectin levels. Inter-
estingly, the effect of AnxA1 to reduce surface levels of 
active αIIbβ3 was due to a decreased affinity of αIIbβ3 for 
PAC1 rather than decreased surface expression of αIIbβ, 
as shown using the αIIbβ3 (CD41a) antibody (Figure 6C). 
In addition, we found that AnxA1 was able to inhibit 
thrombin-induced activation of classic inside-out signal-
ing events such as Akt activation (Figure 6D and 6F), in-
tracellular Ca2+ release (Figure 6G), and Rap1 activation 
(Figure 6E and 6H). These data suggest that AnxA1 may 
have a direct effect on integrin suppression and in so 
doing, reduces the propensity for platelets to aggregate 
and cause thrombosis.
It has previously been shown that P-selectin activates 
intracellular signaling pathways to initiate phagocy-
tosis,33 and PS exposure on the plasma membrane is 
a property of activated platelets and cells undergo-
ing apoptosis. Figure 6I through 6L demonstrates that 
AnxA1 is able to promote the phagocytosis of plate-
lets by neutrophils. These data provide further evidence 
that not only is AnxA1 able to reduce the prothrombot-
ic ability of platelets in vivo, but its effects are translated 
in the human setting and could provide a therapeutic 
mechanism by which AnxA1 is able to reduce thrombus 
formation.
DISCUSSION
We present herein several novel key findings. Firstly, the 
absence of AnxA1 heightens platelet adherence and 
platelet aggregate recruitment to the cerebral endo-
thelium after I/RI. Exogenous administration of AnxA1 
reduces both platelet activation and aggregation, pro-
moting cerebral protection against thromboinflam-
mation. Additionally, AnxA1 treatment prevented the 
development of subsequent thrombotic events after 
cerebral I/RI. Both murine and human stroke are associ-
ated with decreased circulating levels of AnxA1, which 
may help to explain the exacerbated thromboinflam-
matory response seen in stroke. Finally, we show that 
the AnxA1 is able to act on human platelets by inhib-
iting thrombin-induced activation of classic inside-out 
signaling (including Ca2+ influx and Akt activation) and 
selectively mediating cell surface determinants (eg, PS, 
P-selectin) to promote phagocytosis and trigger their 
clearance by neutrophils, thus initiating active resolu-
tion of thromboinflammation. Altogether, these novel 
findings for the first time demonstrate that the pro-
Figure 3 Continued. with vehicle (saline) or AnxA1 (3.3 mg/kg) for 30 min before intravital microscopy, which is shown in step 7. E, Quantification of PNAs in the 
cerebral microcirculation from D using intravital microscopy. F, Adoptive transfer experiments were performed by injecting neutrophils isolated from donor mice 
into neutropenic recipient mice. In steps 1 and 2, recipient mice were rendered neutropenic by administration of ANS. In step 3, neutropenic mice were subjected 
to cerebral I/R by tMCAo/R. In step 6, the mice were then treated with vehicle (saline) or AnxA1 (3.3 mg/kg) for 30 min before intravital microscopy, which is 
shown in step 7. G, Quantification of NPAs (neutrophil platelet aggregates) in the cerebral microcirculation from F using intravital microscopy. H through K, Blood 
samples were taken from wild-type mice subjected to MCAo, followed by a 24-h reperfusion and treatment with vehicle (saline) or AnxA1 and analyzed by flow 
cytometry to assess systemic aggregate formation: quantification of circulating. H, Platelet–leukocyte aggregates (PLAs, CD45.2+, and CD41+). I and J, Flow 
cytometry population groups of PNAs, which are denoted within the CD45.2+, CD41+ population as Ly-6G+, and F4/80− aggregates. K, Quantification of circulating 
PNAs. The data are means±SEM of 5 mice/group and assessed by ANOVA with a Bonferroni post hoc test (A and B), Mann–Whitney test (E), or a Student t test (G, 




 http://ahajournals.org by on July 23, 2021
Senchenkova et al Annexin A1 Modulates Platelet Function in Stroke
Circulation. 2019;140:319–335. DOI: 10.1161/CIRCULATIONAHA.118.039345 July 23, 2019 327
ORIGINAL RESEARCH 
ARTICLE
resolving ligand AnxA1 is able to exert its protection 
through platelets via Fpr2/ALX by orchestrating the del-
icate balance of platelet function from a propathogenic 
to a regulatory role in cerebral I/RI (and potentially I/RI 
in other vascular beds). Thus, AnxA1 could be used as 
a viable treatment therapy in stroke to protect against 
I/RI by reducing the associated thromboinflammation 
(Figures 7 and 8).
There is an urgent medical need to decipher mecha-
nisms underlying thromboinflammatory events to de-
velop new therapeutic opportunities.35,36 A therapeutic 
drug-discovery program we are actively pursuing builds 
Figure 4. Annexin A1 (AnxA1) reduces platelet activation/aggregation postischemia reperfusion injury (I/R). 
Wild-type mice were subjected to sham or transient middle cerebral artery occlusion for 60 min, followed by 24 h of reperfusion. Vehicle (saline) or AnxA1 (3.3 mg/
kg) was administered intravenously at the start of reperfusion. A, At the end of reperfusion, plasma thromboxane B2 (TXB2) levels were measured. B through F, Platelets 
were isolated for quantification as follows. B through D, Using flow cytometry, phosphatidylserine externalization (using annexin AV [AnxAV] staining, presented as a 
percentage of AnxAV-positive platelets) was quantified on single platelets (B), platelet–platelet aggregates (C), or platelet–platelet aggregates after further stimulation with 
thrombin (D, 0.1 U/mL). E, Representative platelet aggregation velocity chart in response to thrombin (0.1 U/mL). F, Velocity of aggregate formation was measured using 
a low-angle light-scattering technique. The data are means±SEM of 5 to 8 mice per group and assessed by ANOVA with Bonferroni post hoc test (A through D and F). 
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on the concept of resolution of thromboinflammation, 
with AnxA1 being a compound of significance.7,9,37,38 
Although recent interest has been dedicated to ef-
fects of AnxA1 with respect to leukocytes (neutrophils, 
macrophages) in inflammation resolution, the role that 
platelets (which express Fpr2/ALX [Figure VI in the on-
line-only Data Supplement], the key receptor involved 
in the resolution process), platelet aggregates, and mi-
crovascular occlusion play in both thrombosis and in-
flammation strongly suggests that these cells could be 
an additional target for AnxA1 and one that has not 
been previously studied. Here, we questioned whether 
we could exploit the biological properties of AnxA1 and 
its receptor FPR2/ALX to instigate possible novel drug-
discovery programs for anti-inflammatory, proresolving 
strategies suitable to treat cardiovascular diseases espe-
cially acute ischemic stroke.37,39 Hence, we began here 
by assessing whether AnxA1 played functional roles in 
cerebral I/RI.
We demonstrated herein that a genetic AnxA1 de-
letion is not associated with spontaneous thrombosis 
or bleeding but leads to exacerbated cerebral inflam-
matory responses after tMCAo/R. Specifically, these 
effects were detected by increased adherent platelets 
and heterotypic platelet aggregates in the pial circuit, 
which were coupled with increased neuronal and neu-
rovascular damage, eg, increased infarct volume and 
a disrupted BBB. Moreover, the BBB of AnxA1−/− mice 
was compromised to a greater degree in the ipsilateral 
side compared with control mice, suggesting a lack of 
AnxA1 either directly or indirectly promotes BBB per-
meability postischemic injury. Furthermore, the BBB 
was also more permeable in the contralateral side (ie, 
noninfarcted side) of AnxA1−/− mice versus WT mice, an 
effect previously unknown. These data fit with other 
recent findings demonstrating that AnxA1−/− mice have 
increased BBB permeability at resting state40 and that 
AnxA1 is essential for maintaining tight junctions in 
the BBB and repairing the permeabilizing effect of sys-
temic lipopolysaccharide on the BBB.40,41 Additionally, 
indirect effects leading to BBB disruption and damaged 
microvascular endothelium9,35,42 could be increased IL-
1β, TNFα, and IL-6 cytokine levels (as seen in AnxA1−/− 
mice), which can induce vascular permeability and ad-
hesion molecule expression.
Multiple cell types are involved in the pathophysi-
ology of I/RI, including resident cells (such as vascular 
smooth muscle cells, astrocytes, microglial cells, neu-
rons, etc.) and blood-borne immune cells (such as 
platelets, neutrophils, monocytes, etc.). We have previ-
ously hypothesized that a second potential target for 
the effects of AnxA1 might be microglial cells. When 
peptide AnxA1Ac2-26 was administered to minocycline-
treated mice, its observed cerebroprotective effects on 
leukocyte adhesion to pia mater venules were attenu-
ated in 2 different models of inflammation: endotoxin 
(lipopolysaccharide)38 and stroke (F.N.E. Gavins et al, 
unpublished data, 2018). Other groups have focused 
on neurons, although controversy has previously sur-
rounded the localization of AnxA1 within these brain 
resident cells, possibly because of differences in anti-
body specificities, post-translational modification of 
AnxA1 in neurons to mask antigenicity, differences in 
tissue processing, or all of the above.43 Some studies 
Figure 5. Annexin A1 (AnxA1) protects against initial cerebral thrombo-
sis and development of subsequent thrombotic events.  
A and B, Still images of cerebral pial vessels showing onset (A) and cessation 
(B) of blood flow in the light/dye-induced thrombus model in wild-type (WT) 
mice. C through E, Effects of AnxA1 (C, 1 µg/mouse) or saline vehicle injected 
20 min before the onset of thrombus formation in cerebral arterioles (D) and 
venules (E). F, The mice were subjected to transient middle cerebral artery 
occlusion for 60 min, followed by 24 h of reperfusion. G and H, At the end 
of reperfusion, the mice were treated with vehicle (saline) or AnxA1 (1 µg/
mouse) 20 min before the onset of light/dye-induced thrombus formation 
in cerebral arterioles (G) and venules (H). The data are means±SEM of 5 to 
7 mice/group and assessed by a Student t test (D, E, G, and H). *P<0.05 vs 
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Figure 6. Annexin A1 (AnxA1) decreases human platelet activation and promotes phagocytosis.  
A through C, Human platelets (1×106) were isolated, washed, preincubated with 100 ng of AnxA1 (30 min at 37°C), and stimulated with thrombin and using 
flow cytometry; levels of P-selectin expression (A), activated integrin αIIbβ3 (PAC-1; B), and surface levels of αIIbβ3 (CD41a; C) were quantified. D through H, 
Freshly isolated platelets (1×106) were treated with AnxA1 at 100 ng and treated with vehicle (saline), thrombin (0.1 U), or thrombin and AnxA1 (100 ng) for 
3 min, and cells were subsequently lysed and blotted for phospho-AKT (P-AKT) and total AKT (n=3 individual donors/group; D and F) and active Ras-associ-
ated protein 1 (Rap1) and Rap1 (n=5 individual donors/group; E and H) or changes cytosolic Ca2+ in fluo-3-acetoxymethyl ester (Fluo-3 AM)–labeled platelets 
was determined in the presence or absence of AnxA1 (G). F and H, Akt and Rap1 were quantified by ImageJ. The ratio of p-AKT/AKT and Active Rap1/Rap1 
was calculated to get the fold change in reference to the untreated control. G, The graph shows the mean fluorescence intensity (fluorescent arbitrary units 
[FAU]) at baseline (no stimulation), in stimulated platelets (thrombin 0.1 U/1×106 platelets), and in platelets incubated with AnxA1 (100 ng/1×106 platelets) 
and stimulated with thrombin. I through K, Representative images of phagocytosis using pHrodo dye from 1 experiment at 1 h. The scale bars indicate 200 
μm. I, Human platelets (1×106) preincubated with 100 ng of AnxA1 and 2.5 μmol/L pHrodo Red AM intracellular pH indicator for 20 min, followed by op-
sonization with 1% human serum, with and without thrombin stimulation, were coincubated with neutrophils (with and without phorbol myristate acetate 
[PMA]) for 1 h at 37°C in a 96-well flat clear-bottomed black-walled plate, and fluorescence emission was measured in the IncuCyteZOOM (Essen BioScience) 
imaging platform. The data are means±SEM of 6 to 7 individual donors/group unless otherwise stated (2 outliers [defined as at least 2 standard deviations] 
were removed for A, and 1 outlier was removed for B and assessed by a Student t test (A and B), Kruskal–Wallis with Dunn’s test (F and G), or ANOVA 
with Bonferroni post hoc test (C, H, and L). *P<0.05, **P<0.01, and ****P<0.0001 vs unstimulated platelets. #P<0.05, ##P<0.01 vs thrombin-stimulated 
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using the AnxA1−/− mouse (in which the gene for β-
galactosidase, LacZ, has been inserted under the con-
trol of the AnxA1 promoter) have already been per-
formed showing β-galactosidase staining in ependymal 
cells lining the ventricles, in intracerebral blood vessels, 
and in a highly restricted set of neurone-like cells in 
the Substantia nigra pars compacta and the pyramidal 
layer of the hippocampus.44 Since these findings were 
shown, other groups have shown AnxA1 to be involved 
in neuronal apoptosis via its phosphorylation45 or an in-
teraction with p53.46
Interestingly, human and murine stroke is associated 
with decreased circulating levels of AnxA1. Given the 
nature of this antithromboinflammatory and proresolv-
ing nature of this protein, these decreased levels may 
help to explain the propagation of the inflammatory re-
sponse in stroke and concurs with reduced levels found 
in other chronic inflammatory conditions, eg, sickle cell 
disease, Crohn’s disease, obesity, and sepsis.47–50
AnxA1 administration reduced both individual plate-
let and neutrophil adhesion in tMCAo/R mice. How-
ever, because cerebral-endothelial PNA adherence is a 
Figure 7. Annexin A1 (AnxA1) mitigates thromboinflammatory responses and promotes resolution during ischemia reperfusion injury. 
Schematic overview shows the effects of AnxA1 on both thrombotic and inflammatory events as follows. Step 1 reduces platelet–neutrophil aggregate (PNA) 
adhesion on endothelial cells in the cerebral microvasculature; steps 2 and 3 decrease neutrophil (step 2) and platelet adhesion (step 3); step 4 diminishes platelet 
activation and aggregate velocity, promoting a phosphatidylserine and P-selectin–dependent clearance program; step 5 promotes neutrophil phagocytosis of plate-
lets for resolution; and step 6 protects against enhanced intravascular thrombus formation and secondary thrombotic events in the cerebral microvasculature. ALX 
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key effector of microvascular occlusion, we determined 
whether AnxA1 treatment would have any affect. In-
deed, AnxA1 blocked cerebral endothelial recruitment 
of PNAs post-tMCAo/R, an effect mediated through 
Fpr2/ALX. These findings are important because both 
PNA formation and platelet activation are increased in 
ischemic stroke and are involved at several levels in the 
pathogenesis and severity of stroke.51 Although PNAs 
Figure 8. Annexin A1 (AnxA1) reduces platelet activation and integrin activity. 
In thromboinflammation, platelets are stimulated via G-protein–coupled receptors (eg, protease-activated receptors 1, 3, and 4; human thromboxane A2 receptor 
[TPs]; P2Y12; P2Y1; and P2X1) and immunoreceptor tyrosine-based activation motif-coupled receptors with agonists such as thrombin, thromboxane A2 (TXA2), 
and ADP. This stimulation results in downstream signaling events that increase cytosolic Ca2+ levels leading to platelet secretion (step 2), shape change (step 2), 
activation (step 3), and adhesion and aggregation (step 4). The small GTPase Ras-related protein 1 (RAP1) regulates multiple functional responses in platelets, in 
particular integrin activation. As with many platelet components, Rap1 regulators CalDAG–GEFI (calcium- and DAG-regulated guanine exchange factor-1) and 
RASA3 are affected by small changes in the cytosolic Ca2+ concentration, leading to rapid αIIbβ3 integrin activation. To sustain αIIbβ3 activation, ADP (which is rapidly 
released and secreted from storage granules on increased Ca2+ concentrations) must engage P2Y12 receptors and phosphatidylinositol 3-kinase (PI3K) signaling, 
which reduces RASA3 activity. AnxA1 acts via platelet formyl peptide receptor 2 (also known as the lipoxin A4 receptor; FPR2/ALX) to affect each of these 4 named 
platelet events, thereby inhibiting thromboinflammation. In particular, our data showed that AnxA1 reduced Akt expression, Ca2+ levels, Rap1 expression, and 
the affinity of αIIbβ3 (the most abundant of the β1 integrins and β3 integrins expressed on the platelet surface) for PAC-1. The effects of AnxA1 on platelets point 
toward a novel and previously undiscovered role for AnxA1 to act as an antithrombotic agent by suppressing integrin activation and thereby reducing platelet 
activation, a prerequisite for platelet aggregation and thrombosis. AA indicates arachidonic acid; COX-1, cyclooxygenase 1; DAG, diacylglycerol; IP3R, receptor for 
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have been widely used as a surrogate marker for sys-
temic inflammatory responses,52 the pathophysiological 
importance of these aggregates is unclear.53 The fact 
that AnxA1 reduced endothelial PNA formation in the 
brain further supports the concept of this protein act-
ing as a key resolving mediator of thromboinflamma-
tion after cerebral I/RI.
Although administration of AnxA1 prevented cere-
bral PNAs adhesion, it did not stop aggregates form-
ing in the circulation. It is tempting to speculate that 
the differences observed with AnxA1 administration 
on local and systemic PNA formation might be due 
to clearance and phagocytosis to promote resolution 
of thrombosis and inflammation. Platelet clearance is 
comprised of 2 specific events: adhesion to neutrophils 
(via P-selectin and PSGL-1) and internalization into the 
white blood cell.54–57 The extent of platelet clearance 
can correlate with platelet activation, often monitored 
through elevated P-selectin expression.55 We found here 
that AnxA1 limited the prothrombotic and proinflam-
matory impact of both platelet–platelet and platelet–
neutrophil aggregates. Also, AnxA1 did not change P-
selectin expression on platelets, which may be because 
recognition of P-selectin activates intracellular signaling 
pathways to initiate phagocytosis.55 Evidence suggests 
that to promote phagocytosis, AnxA1 acts as a ligand 
for 2 specific sites, binding through its core domain to 
PS on the surface of apoptotic neutrophils and to Fpr2/
ALX via its N-terminal sequence.58 Maderna et al.58 have 
shown that Fpr2/ALX expression and phosphokinase C–
dependent internalization of Fpr2/ALX is required for 
phagocytosis and clearance of activated neutrophils by 
bone marrow–derived macrophages. In addition, Ca2+ 
mobilization (activation of phospholipase C) promotes 
platelet apoptosis and elimination of platelets from cir-
culation, and AnxA1 and its bioactive peptides are able 
to mobilize intracellular Ca2+ in neutrophils.59 As such, 
engagement of Fpr2/ALX by AnxA1 on platelets may 
therefore cause Ca2+ mobilization, promoting platelet 
apoptosis.60
Having studied the effects of AnxA1 on PNAs and 
neutrophil involvement in PNAs, we next focused on 
the platelet, especially because no studies had previous-
ly defined the bio-actions of AnxA1 on platelets. Plate-
lets not only participate in hemostasis and thrombosis 
but can also modulate acute and chronic inflammatory 
responses. However, the mechanisms underlying the 
prothrombotic phenotype generated by cerebral I/RI re-
main poorly understood. Here, we found that platelet 
adhesion and platelet heterotypic aggregates were up-
regulated in stroke (and further increased in AnxA1−/− 
mice, although no differences were found in platelet 
counts) and were reduced in the brain of tMCAo/R 
mice after administration of AnxA1. It is known that 
when platelets are activated, they release thromboxane 
A2 and externalize PS, which, in cooperation with oth-
er clotting factors (Va and Xa, and Ca2+-forming pro-
thrombinase complex),61,62 initiate the intrinsic coagula-
tion pathway forming thrombin, platelet–platelet, and 
platelet–neutrophil aggregates and intensifying platelet 
accumulation to develop stable thrombi.
Previously, no direct information was available on 
Fpr2/ALX-mediated intracellular effects regulating 
platelet aggregation. Because Fpr2/ALX is a G-protein–
coupled receptor, it is tempting to speculate that the 
engagement of Fpr2/ALX with AnxA1 may trigger acti-
vation of adenylate cyclase (as evidence by AnxA1 treat-
ment decreasing thromboxane B4 plasma levels) and el-
evation of cAMP or/and cGMP levels in platelets leading 
to the decreased aggregation velocity, as observed in 
our study.60,61,63 We found that not only were plasma 
levels of thromboxane B4 decreased after AnxA1 treat-
ment, but AnxA1 also reduced PS exposure on single 
platelets, as well as on their aggregates, along with re-
ducing the velocity of aggregate formation. The results 
suggest that after cerebral ischemia, AnxA1 is a non-
redundant factor that promotes an anti-inflammatory/
antithrombotic and proresolving environment.
Integrins are critical in thrombosis and hemosta-
sis, supporting platelet–matrix (platelet adhesion) and 
platelet–platelet interactions (platelet aggregation).64,65 
Currently available antithrombotic agents target the 
interaction of platelet integrin αIIbβ3 with fibrinogen 
during platelet aggregation but are associated with 
life-threatening adverse effects of bleeding.2,3,66 Integ-
rin αIIbβ3 (the most abundant integrin expressed on the 
platelet surface)67 plays a central role in thrombosis and 
hemostasis, because of its ability to mediate platelet 
adhesion and aggregation. In resting states, this major 
membrane protein expressed on the platelet cell surface 
membrane and intracellular compartments.68 However, 
on activation (eg, by thrombin), inside-out signaling is 
initiated and induces a cation‐dependent transforma-
tion of receptors from a low-affinity to a high-affinity 
state, which is dependent on elevated intracellular 
Ca2+.67–69 Conversely, outside-in signaling mediates 
platelet spreading and also greatly amplifies platelet 
thrombi.70 Because the activation of integrin αIIbβ3 is 
the final common pathway of platelet activation, the 
assessment of its activation is critical for accurate stud-
ies on platelet function.68,71 We found here that AnxA1 
was able to inhibit thrombin-stimulated increases in ac-
tive αIIbβ3 integrins on human platelets (as assessed by 
the ligand‐mimetic monoclonal antibody PAC-1, which 
detects specifically high‐affinity conformation of integ-
rin αIIbβ3.
68 In addition, the use of CD41a and PAC-1 in 
flow cytometry allowed us to discriminate between the 
resting and the activated form of the receptor because 
platelet activation is a prerequisite for platelet binding.68
Activation of the small GTPase Rap1 promotes its 
interaction with talin1, inducing talin1’s interaction 
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tail that drives a conformational change in the inte-
grin extracellular domain enhancing its affinity for li-
gand.67 Thrombin enhances αIIbβ3 affinity through the 
Ca2+-dependent activation of the guanine nucleotide 
exchange factor CalDAG, which facilitates Rap1 ac-
tivation. However, sustained Rap1 signaling requires 
Ca2+-dependent ADP release and P2Y12-dependent 
phosphatidylinositol 3-kinase signaling, which inacti-
vates the Rap1 inhibitor RASA3. We found that AnxA1 
was able to inhibit thrombin-induced activation of Ca2+ 
influx, ADP release, and activation of the phosphati-
dylinositol 3-kinase effector Akt (Figure  6D through 
6G). Consistent with this, our data show that AnxA1 is 
able to decrease the Rap1 activation in thrombin-stim-
ulated platelets. In addition to inside-out integrin ac-
tivation, integrin engagement also leads to outside-in 
integrin signaling, resulting in changes in intracellular 
signaling pathways (eg, activation of Akt and increased 
intracellular Ca2+ release). This increase in intracellular 
Ca2+ along with PS exposure are associated with an 
enhanced procoagulant activity, thereby driving throm-
bogenesis and microvascular occlusion. The regulation 
of integrin signaling is a critical aspect in multiple steps 
of platelet function and thrombus formation.71,72 Col-
lectively, these data point toward a novel and previ-
ously undiscovered role for AnxA1 to act as an anti-
thrombotic agent by suppressing integrin activation 
and thereby reducing platelet activation, a prerequisite 
for platelet aggregation and thrombosis. Additionally, 
these data could pave the way to novel and more per-
sonalized approaches to antiplatelet therapy.
Interestingly, the prothrombotic ability of plate-
lets also directly relates to the degree of PS exposure, 
such that a reduction of PS exposure on the surface of 
platelets links to reduction of thrombus formation.61,62 
Here, we found a previously unknown role of AnxA1 
to increase blood flow cessation time because we were 
able to demonstrate, for the first-time, the dynamics 
of AnxA1 on thrombosis induced using the light/dye 
method.25 AnxA1 administration was equally effective 
in both arterioles and venules, despite the known physi-
cal and rheological differences in each of these vessels 
types.1,73 As such, our findings emphasize the possible 
therapeutic potential of AnxA1 as a preventative mea-
sure, as well as a novel treatment strategy for stroke.
Finally, having demonstrated the protective effect 
elicited by AnxA1 postcerebral I/RI coupled with the 
protection afforded by the protein against cerebral 
thrombosis (a prerequisite for cerebral ischemia), we 
determined whether we could further exploit the ef-
fects of AnxA1. As such, we treated mice with AnxA1 
before stroke and then performed light/dye thrombosis. 
Our novel findings show that AnxA1 was able to in-
crease blood flow cessation after a subsequent throm-
botic event postcerebral ischemia, thereby showing the 
diverse nature of AnxA1.
In summary, our results demonstrate that the lack 
of AnxA1 leads to aberrant platelet recruitment and 
aggregation in the brain after ischemic stroke and 
that exogenous administration of AnxA1 is a pow-
erful proresolving mediator of thromboinflammation. 
We report previously unknown effects of AnxA1 on 
platelets, including a possible endogenous circuit in 
which AnxA1 modulates the expression of platelet 
moieties (eg, PS and P-selectin) and as such can pro-
mote phagocytosis and trigger platelet clearance by 
neutrophils. Furthermore, we provide novel evidence 
that AnxA1 is not only able to reduce the effects of 
cerebral I/RI (including reducing the effect of subse-
quent thrombi forming after cerebral ischemia), but 
it is able to reduce cerebral thrombosis, a prerequisite 
for stroke. These novel physiopharmacological prop-
erties for the AnxA1 and FPR2/ALX pathway increase 
our understanding of the cellular intravascular events 
typical of stroke and open new avenues for an at-
tractive therapeutic treatment strategy not only for 
patients with stroke but also for patients susceptible 
to stroke.
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